GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug combo shows promise against aggressive esophageal cancer
Disease control CompletedThis study tested whether adding the targeted drug trastuzumab to standard chemoradiation helps people with HER2-positive esophageal cancer. About 200 adults with early-stage cancer took part. The goal was to see if the combination delays cancer return or improves survival.
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New combo therapy shows promise in advanced cancer trial
Disease control CompletedThis early-stage study tested a new treatment called VE800 combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goal was to see if the combination is safe and whether it can shrink …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Vedanta Biosciences, Inc. • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Triple-Drug cocktail shows promise for tough stomach cancers
Disease control CompletedThis study tested a combination of three drugs—regorafenib, nivolumab, and chemotherapy—in 30 people with advanced or recurrent stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery. The goal was to see if the combination was safe and effec…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New combo therapy shows promise in stomach cancer battle
Disease control CompletedThis study tested whether adding the drug AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. It involved 610 adults who had not received prior treatment. The goal was to see if the combination improves survival and s…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
New combo therapy shows promise for tough stomach cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and trastuzumab could help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 738 adults with previous…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets tough stomach cancer
Disease control CompletedThis study tested a new combination of two drugs, GEN-001 and avelumab, in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for stomach cancer patients with low HER2 levels?
Disease control CompletedThis study tested a combination of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with advanced HER2-low stomach or gastroesophageal junction cancer who had not received prior treatment. The goal was to find th…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis study tested whether combining two drugs, TAS 102 and ramucirumab, is safe and works for people with advanced stomach or gastroesophageal junction cancer that no longer responds to other treatments. 23 participants were enrolled. The goal was to see how long they lived and h…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New cancer drug SGN-B6A tested for safety in chinese patients
Symptom relief CompletedThis early-stage study tested a new drug called SGN-B6A in 6 Chinese adults with advanced solid tumors (lung, head/neck, esophageal, or stomach cancers) that had stopped responding to standard treatments. The main goal was to check the drug's safety and side effects, and to see h…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC